• INmune Bio entered a master services agreement with Uniphar to support international access, distribution and commercialization of Ebstrocel.
• Initial plans target named-patient access in selected European countries and the Middle East and North Africa, subject to local law.
• Ebstrocel is an allogeneic stromal cell therapy for recessive dystrophic epidermolysis bullosa.
• The framework could expand to broader commercial distribution as country-specific regulatory approvals, pricing and reimbursement are secured.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210700PRIMZONEFULLFEED9849922) on October 21, 2026, and is solely responsible for the information contained therein.